1. Scrip
  2. >>Business

Novartis Tunes Into Radiopharmaceuticals With Endocyte Buy

 
• By Kevin Grogan

Endocyte paid just $12m upfront a year ago for a potential first-in-class investigational radioligand therapy for prostate cancer. Novartis is buying Endocyte for a whopping $2.1bn., highlighting the company's emphasis on building in radiopharmaceuticals.

Wallet
Novartis has opened its wallet again for another bolt-on • Source: Shutterstock

Novartis AG is ramping up in radiopharmaceuticals, buying US cancer specialist Endocyte Inc. for $2.1bn in a deal, building on the acquisition of Advanced Accelerator Accelerator Applications for $3.9bn last year. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business